Status:
ACTIVE_NOT_RECRUITING
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
Lead Sponsor:
RECORDATI GROUP
Conditions:
Endogenous Cushing's Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in p...
Detailed Description
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in p...
Eligibility Criteria
Inclusion
- Written informed consent obtained prior to registration of any patient data
- Male or female patients aged 18 years or older with endogenous CS treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.
Exclusion
- Patients with exogenous CS
- Patients with Pseudo CS
- Patients participating in an interventional clinical trial with an investigational drug.
Key Trial Info
Start Date :
June 13 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2027
Estimated Enrollment :
206 Patients enrolled
Trial Details
Trial ID
NCT05382156
Start Date
June 13 2022
End Date
August 1 2027
Last Update
November 20 2025
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
2
Emory University School
Atlanta, Georgia, United States, 30322
3
Northwestern University
Chicago, Illinois, United States, 60611
4
Indiana University Schl-med
Indianapolis, Indiana, United States, 46202